Posted on September 23rd, 2010 in Agrium, AGU, Altria, analyst upgrades, aye, BX, Cal-Maine, CALM, Chilcott, cvvt, DD, downgrades, DuPont, DYN, Endo, ENDP, Entergy, ETR, EW, FE, frx, India Shares, initiations, inthenews, IPI, LO, Lorillard, MHS, MMYT, Mo, MOS, Mosaic, MYL, Mylan, NVDA, Nvidia, OptionXpress, OXPS, PPL, VMED, WCRX
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Altria Group (MO), duPont(E.I.)deNemours (DD), Analyst Initiations
Analyst Upgrades
- Piper Jaffray upgraded Edwards Lifesciences (EW) to overweight from neutral and raised its target price for shares to $77 from $53 after The New England Journal of Medicine reported the company’s PARTNER Trial met primary endpoints.
- UBS upgraded Endo Pharmaceuticals (ENDP) to buy from neutral and raised its price target to $36 from $25. UBS is positive on Endo’s creative strategic deals and believes the switch to Opana TRF from Opana ER will be easy. Additionally, the analyst believes pipeline expectations are very low.
- BMO Capital upgraded Nvidia (NVDA) to outperform from market perform based on expectations that share loss in the core GPU business will stop, Tegra momentum and valuation. The firm raised its price target to $16 from $9.
- FirstEnergy (FE) and Allegheny Energy (AYE) were upgraded to outperform from neutral at Credit Suisse.
- Mylan (MYL) was upgraded to conviction buy from buy at Goldman. Warner
- Chilcott (WCRX) was upgraded to overweight from equal weight at Morgan Stanley.
Continue reading Analyst Calls: CALM, CWT, DD, DYN, ENDP, EW, MO, MOS, NVDA, OXPS, PPL …
Analyst Calls: CALM, CWT, DD, DYN, ENDP, EW, MO, MOS, NVDA, OXPS, PPL … originally appeared on BloggingStocks on Thu, 23 Sep 2010 11:50:00 EST. Please see our terms for use of feeds.
Permalink | Email this | Comments
Morgan Stanley – Endo Pharmaceuticals – Nvidia – Altria Group – BloggingStocks
Tags: India Share market, India Shares
With widespread concerns over investments in the People’s Republic of China right now, some traders have sworn off Chinese companies all together. That’s a big mistake. Indeed, the current state of China stocks is uncertain and there is a lot of fear and frustration over China investments right now. But the issue is that all Chinese companies are not the same. There are a wide variety of China stocks listed in the U.S. — state-owned enterprises, mid-cap blue chips and small-caps, each with specific characteristics. 
With widespread investor concerns over the current state of Chinese stocks, there is a lot of fear and frustration over China investments right now. The issue is that all China stocks are not the same. There are different types of China stocks listed in the U.S. — state-owned enterprises, mid-cap blue chips and small-caps, each with specific characteristics. Overall, I still believe that we will see 40% upside in many of these stocks by year end, most of it in fourth quarter, and now is the time to position for the upcoming rally.
